These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37457135)

  • 61. The Role of the Microbiome in Pancreatic Cancer.
    Miyabayashi K; Ijichi H; Fujishiro M
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139638
    [TBL] [Abstract][Full Text] [Related]  

  • 62. ATM- and ATR-induced primary ciliogenesis promotes cisplatin resistance in pancreatic ductal adenocarcinoma.
    Chao YY; Huang BM; Peng IC; Lee PR; Lai YS; Chiu WT; Lin YS; Lin SC; Chang JH; Chen PS; Tsai SJ; Wang CY
    J Cell Physiol; 2022 Dec; 237(12):4487-4503. PubMed ID: 36251015
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents.
    Khalafalla FG; Khan MW
    Cancer Growth Metastasis; 2017; 10():1179064417709287. PubMed ID: 28579826
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.
    Opitz FV; Haeberle L; Daum A; Esposito I
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944807
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
    Wang W; Yan L; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
    Front Oncol; 2020; 10():618215. PubMed ID: 33718118
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic significance and immune infiltration of microenvironment-related signatures in pancreatic cancer.
    Lu Q; Zhang Y; Chen X; Gu W; Ji X; Chen Z
    Medicine (Baltimore); 2021 Mar; 100(12):e24957. PubMed ID: 33761652
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
    Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
    BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
    [TBL] [Abstract][Full Text] [Related]  

  • 71. COL11A1-driven positive feedback loop modulates fibroblast transformation and activates pancreatic cancer progression.
    Sun D; Dai T; Ji Y; Shen W; Bian W
    Cell Biol Int; 2023 Jun; 47(6):1081-1091. PubMed ID: 36861686
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.
    Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH
    BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment.
    Li Y; Zhao W; Wang Y; Wang H; Liu S
    J Nanobiotechnology; 2022 May; 20(1):208. PubMed ID: 35501802
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 76. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
    Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
    Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells.
    Zhao Z; Lin Z; Guo X; Al-Danakh A; He H; Qin H; Ma C; Zhang N; Tan G
    J Immunol Res; 2023; 2023():4311388. PubMed ID: 37050932
    [TBL] [Abstract][Full Text] [Related]  

  • 80. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.